Division of Cardiac Surgery, University of Alberta, Edmonton, Alberta, Canada.
Division of Cardiac Surgery, Western University, London, Ontario, Canada.
Ann Thorac Surg. 2019 Dec;108(6):1768-1775. doi: 10.1016/j.athoracsur.2019.04.121. Epub 2019 Jun 27.
Organ malperfusion remains challenging, causing complications associated with acute DeBakey I dissections. We describe the results of malperfusion management after implantation of the Ascyrus Medical Dissection Stent (AMDS; Ascyrus Medical, Boca Raton, FL), an adjunct to current surgical aortic dissection repair.
From March 2017 to January 2019, 47 consecutive patients (median age, 65 years; interquartile range, 15.8 years; 61.9% male) presented with acute DeBakey I aortic dissections and underwent emergent surgical aortic repair with AMDS implantation. Malperfusion was detected preoperatively in 55.3% (n = 26) of patients. Two patients were excluded from efficacy analysis due to lack of follow-up. Overall, 66 vessel malperfusions were identified, consisting of 1.5% (n = 1) coronary, 33.3% (n = 22) supraaortic, 21.2% (n = 14) visceral, 24.2% (n = 16) renal, and 15.1% (n = 10) extremities. Three patients (11.5%) had clinical evidence of paralysis at presentation.
All 26 device implants were successful. In the malperfusion cohort, 30-day mortality was 7.7% (n = 2). A new neurologic deficit identified postoperatively in patients without neurologic symptoms preoperatively occurred in 7.7% (n = 2). During the follow-up period, 95.5% (n = 63) of vessel malperfusions had resolved without an additional procedure, including 95.5% (n = 21) supraaortic, 92.9% (n = 13) visceral, 93.8% (n = 15) renal, and 100% (n = 10) extremity. All patients with paralysis at presentation had complete resolution.
The AMDS provides an effective single-stage malperfusion management strategy. In this study, dynamic malperfusion involving supraaortic, visceral, spinal cord, and lower extremities were treated concurrently with the index standard-of-care operation without delay in life-saving care.
器官灌注不良仍然是一个挑战,导致与急性德贝基 I 型夹层相关的并发症。我们描述了在植入 Ascyrus 医疗夹层支架(AMDS;Ascyrus Medical,博卡拉顿,佛罗里达州)后灌注不良管理的结果,这是当前主动脉夹层修复手术的辅助手段。
从 2017 年 3 月至 2019 年 1 月,47 例连续患者(中位年龄 65 岁;四分位距 15.8 岁;61.9%为男性)表现为急性德贝基 I 型主动脉夹层,并接受了紧急外科主动脉修复术和 AMDS 植入术。55.3%(n=26)的患者术前发现灌注不良。由于缺乏随访,有 2 例患者被排除在疗效分析之外。总的来说,共发现 66 个血管灌注不良,其中 1.5%(n=1)为冠状动脉,33.3%(n=22)为主动脉上,21.2%(n=14)为内脏,24.2%(n=16)为肾,15.1%(n=10)为四肢。3 名患者(11.5%)在发病时出现瘫痪的临床证据。
所有 26 例装置植入均成功。在灌注不良组中,30 天死亡率为 7.7%(n=2)。在术前无神经系统症状的患者中,术后新发现的新的神经功能缺损发生率为 7.7%(n=2)。在随访期间,95.5%(n=63)的血管灌注不良未经进一步治疗而得到解决,其中 95.5%(n=21)为主动脉上,92.9%(n=13)为内脏,93.8%(n=15)为肾,100%(n=10)为四肢。所有发病时瘫痪的患者均完全缓解。
AMDS 提供了一种有效的单一阶段灌注不良管理策略。在这项研究中,涉及主动脉上、内脏、脊髓和下肢的动态灌注不良与标准的护理手术同时进行,没有延误挽救生命的治疗。